Combination vaccines for childhood immunization : recommendations of the Advisory Committee on Immunization Practices (ACIP), the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP)

An increasing number of new and improved vaccines to prevent childhood diseases are being introduced. Combination vaccines represent one solution to the problem of increased numbers of injections during single clinic visits. This statement provides general guidance on the use of combination vaccines and related issues and questions. To minimize the number of injections children receive, parenteral combination vaccines should be used, if licensed and indicated for the patient's age, instead of their equivalent component vaccines. Hepatitis A, hepatitis B, and Haemophilus influenzae type b vaccines, in either monovalent or combination formulations from the same or different manufacturers, are interchangeable for sequential doses in the vaccination series. However, using acellular pertussis vaccine product(s) from the same manufacturer is preferable for at least the first three doses, until studies demonstrate the interchangeability of these vaccines. Immunization providers should stock sufficient types of combination and monovalent vaccines needed to vaccinate children against all diseases for which vaccines are recommended, but they need not stock all available types or brandname products. When patients have already received the recommended vaccinations for some of the components in a combination vaccine, administering the extra antigen(s) in the combination is often permissible if doing so will reduce the number of injections required. To overcome recording errors and ambiguities in the names of vaccine combinations, improved systems are needed to enhance the convenience and accuracy of transferring vaccine-identifying information into medical records and immunization registries. Further scientific and programmatic research is needed on specific questions related to the use of combination vaccines."The following CDC staff member prepared this report: Bruce G. Weniger, M.D., M.P.H., Epidemiology and Surveillance Division, National Immunization Program." - p. ivIncludes bibliographical references (p. 8-12).10353568Infectious DiseasePrevention and ControlSupersededACI

Guidelines for vaccinating pregnant women: abstracted from recommendations of the Advisory Committee on Immunization Practices (ACIP)

The table on the following page may be used to find the general rule for vaccinating a pregnant woman with a particular vaccine. The third column of the table refers the reader to the page in this document where more specific information from the appropriate ACIP recommendations will be found. Each quotation from an ACIP recommendation in turn references the entire document, where the quotation(s) may be found in context.March 2013.Available via the World Wide Web as an Acrobat .pdf file (141.93 KB, 13 p.).Includes bibliographical references (p. 9-10)

Measles, mumps, and rubella: vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps : recommendations of the Advisory Committee on Immunization Practices (ACIP)

These revised recommendations of the Advisory Committee on Immunization Practices (ACIP) on measles, mumps, and rubella prevention supersede recommendations published in 1989 and 1990. This statement summarizes the goals and current strategies for measles, rubella, and congenital rubella syndrome (CRS) elimination and for mumps reduction in the United States. Changes from previous recommendations include: Emphasis on the use of combined MMR vaccine for most indications; A change in the recommended age for routine vaccination to 12-15 months for the first dose of MMR, and to 4-6 years for the second dose of MMR; A recommendation that all states take immediate steps to implement a two dose MMR requirement for school entry and any additional measures needed to ensure that all school-aged children are vaccinated with two doses of MMR by 2001; A clarification of the role of serologic screening to determine immunity; A change in the criteria for determining acceptable evidence of rubella immunity; A recommendation that all persons who work in health-care facilities have acceptable evidence of measles and rubella immunity; Changes in the recommended interval between administration of immune globulin and measles vaccination; and Updated information on adverse events and contraindications, particularly for persons with severe HIV infection, persons with a history of egg allergy or gelatin allergy, persons with a history of thrombocytopenia, and persons receiving steroid therapy.May 22, 1998.The following CDC staff members prepared this report: John C. Watson, Stephen C. Hadler, Clare A. Dykewicz, Susan Reef, Lynelle Phillips, Epidemiology and Surveillance Division, National Immunization Program.Includes bibliographical references (p. 48-58)

Recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older -- United States, 2013

Each year, recommendations for routine use of vaccines in children, adolescents, and adults in the United States are developed by the Advisory Committee on Immunization Practices (ACIP). This year, for the first time, recommended immunization schedules for persons aged 0 through 18 years and adults aged 19 years and older are being published togetherIntroduction -- Placing these schedules on your website -- Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for persons aged 0 through 18 years - United States, 2013 / ACIP Childhood/Adolescent Immunization Work Group: Iyabode Akinsanya-Beysolow, Ren\ue9e Jenkins, H. Cody Meissner -- Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older --United States, 2013 / ACIP Adult Immunization Work Group: Carolyn B. Bridges, LaDora Woods, Tamera Coyne-BeasleyFebruary 1, 2013.Available via the World Wide Web as an Acrobat .pdf file (1 MB, 21 p.).Includes bibliographical references.Infectious DiseasePrevention and ControlCurrentACIP2336430

A Comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part II. Immunization of adults

Hepatitis B vaccination is the most effective measure to prevent hepatitis B virus (HBV) infection and its consequences, including cirrhosis of the liver, liver cancer, liver failure, and death. In adults, ongoing HBV transmission occurs primarily among unvaccinated persons with behavioral risks for HBV transmission (e.g., heterosexuals with multiple sex partners, injection-drug users [IDUs], and men who have sex with men [MSM]) and among household contacts and sex partners of persons with chronic HBV infection. This report, the second of a two-part statement from the Advisory Committee on Immunization Practices (ACIP), provides updated recommendations to increase hepatitis B vaccination of adults at risk for HBV infection. The first part of the ACIP statement, which provided recommendations for immunization of infants, children, and adolescents, was published previously (CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices [ACIP]. Part 1: immunization of infants, children, and adolescents. MMWR 2005;54[No. RR-16]:1--33). In settings in which a high proportion of adults have risks for HBV infection (e.g., sexually transmitted disease/human immunodeficiency virus testing and treatment facilities, drug-abuse treatment and prevention settings, health-care settings targeting services to IDUs, health-care settings targeting services to MSM, and correctional facilities), ACIP recommends universal hepatitis B vaccination for all unvaccinated adults. In other primary care and specialty medical settings in which adults at risk for HBV infection receive care, health-care providers should inform all patients about the health benefits of vaccination, including risks for HBV infection and persons for whom vaccination is recommended, and vaccinate adults who report risks for HBV infection and any adults requesting protection from HBV infection. To promote vaccination in all settings, health-care providers should implement standing orders to identify adults recommended for hepatitis B vaccination and administer vaccination as part of routine clinical services, not require acknowledgment of an HBV infection risk factor for adults to receive vaccine, and use available reimbursement mechanisms to remove financial barriers to hepatitis B vaccination.prepared by Eric E. Mast, Cindy M. Weinbaum, Anthony E. Fiore, Miriam J. Alter, Beth P. Bell, Lyn Finelli, Lance E. Rodewald, John M. Douglas, Robert S. Janssen, John W. WardThe material in this report originated in the National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (proposed), Kevin A. Fenton, MD, PhD, Director; the Division of Viral Hepatitis, John W. Ward, MD, Director; the Division of STD Prevention, John M. Douglas, Jr., MD, Director; and the Division of HIV/AIDS Prevention, Robert S. Janssen, MD, Director; the National Center for Immunization and Respiratory Diseases, Anne Schuchat, MD, Director; and the Immunization Services Division, Lance E. Rodewald, MD, Director.Includes bibliographical references (p. 18-25).17159833Infectious DiseasePrevention and ControlCurrentACI

Yellow fever vaccine : recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002

This report updates CDC's recommendations for using yellow fever vaccine (CDC. Yellow Fever Vaccine: Recommendations of the Advisory Committee on Immunizations Practices: MMWR 1990;39[No. RR-6]1-6). The 2002 recommendations include new or updated information regarding 1) reports of yellow fever vaccine-associated viscerotropic disease (previously reported as febrile multiple organ system failure); 2) use of yellow fever vaccine for pregnant women and persons infected with human immunodeficiency virus (HIV); and 3) concurrent use of yellow fever vaccine with other vaccines. A link to this report and other information related to yellow fever can be accessed at the website for Travelers' Health, Division of Global Migration and Quarantine, National Center for Infectious Diseases, CDC, at http://www.cdc.gov/travel/index.htm, and through the website for the Division of Vector-Borne Infectious Diseases, National Center for Infectious Diseases, CDC, at http://www.cdc.gov/ncidod/ dvbid/yellowfever/index.htm.Introduction -- Yellow fever vaccine -- Precautions and contraindications -- Surveillance and research priorities -- References -- Appendix: Waiver letters from physiciansprepared by Martin S. Cetron, Anthony A. Marfin, Kathleen G. Julian, Duane J. Gubler, Donald J. Sharp, Rachel S. Barwick. Leisa H. Weld, Robert Chen, Richard D. Clover, Jaime Deseda-Tous, Victor Marchessault, Paul A. Offit, and Thomas P. Monath."November 8, 2002."The material in this report originated in the National Center for Infectious Diseases, James M. Hughes, M.D., Director, and the Division of Global Migration and Quarantine, Tony D. Perez, Director.Includes bibliographical references (p. 9-10).Infectious DiseasePrevention and ControlSupersededACIPEMBeltrami9/02/20151243719

Prevention of varicella : updated recommendations of the Advisory Committee on Immunization Practices (ACIP)

"In February 1999, the Advisory Committee on Immunization Practices (ACIP) expanded recommendations for varicella (chickenpox) vaccine to promote wider use of the vaccine for susceptible children and adults. The updated recommendations include establishing child care and school entry requirements, use of the vaccine following exposure and for outbreak control, use of the vaccine for some children infected with the human immunodeficiency virus (HIV), and vaccination of adults and adolescents at high risk for exposure. These recommendations also provide new information on varicella vaccine postlicensure safety data." - p. 1"The following CDC staff members prepared this report: Karin Galil,.Gina P. Mootrey,.Jane Seward, Melinda Wharton, Epidemiology and Surveillance Division, National Immunization Program." - p. ivIncludes bibliographical references (p. 5).10366137Infectious DiseasePrevention and ControlSupersededACI

Immunization of health-care workers: recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Hospital Infection Control Practices Advisory Committee (HICPAC)

"This report summarizes recommendations of the Advisory Committee on Immunization Practices (ACIP) concerning the use of certain immunizing agents in health-care workers (HCWs) in the United States. It was prepared in consultation with the Hospital Infection Control Practices Advisory Committee (HICPAC) and is consistent with current HICPAC guidelines for infection control in health-care personnel. These recommendations can assist hospital administrators, infection control practitioners, employee health physicians, and HCWs in optimizing infection prevention and control programs. Background information for each vaccine-preventable disease and specific recommendations for use of each vaccine are presented. The diseases are grouped into three categories: a) those for which active immunization is strongly recommended because of special risks for HCWs; b) those for which immunoprophylaxis is or may be indicated in certain circumstances; and c) those for which protection of all adults is recommended. This report reflects current ACIP recommendations at the time of publication. ACIP statements on individual vaccines and disease updates in MMWR should be consulted for more details regarding the epidemiology of the diseases, immunization schedules, vaccine doses, and the safety and efficacy of the vaccines." - p. 1The following CDC staff members prepared this report: Walter W. Williams, Raymond A. Strikas, Epidemiology and Surveillance Division National Immunization Program; Miriam J. Alter, Division of Viral and Rickettsial Diseases National Center for Infectious Diseases. - p. iiiCover title.Includes bibliographical references.Bernard M. Branson ([email protected])6/27/2014Infectious DiseasePrevention and ControlSupersededACIPHICPA

A Comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). Part I. Immunization of infants, children and adolescents

This report is the first of a two-part statement from the Advisory Committee on Immunization Practices (ACIP) that updates the strategy to eliminate hepatitis B virus (HBV) transmission in the United States. The report provides updated recommendations to improve prevention of perinatal and early childhood HBV transmission, including implementation of universal infant vaccination beginning at birth, and to increase vaccine coverage among previously unvaccinated children and adolescents. Strategies to enhance implementation of the recommendations include 1) establishing standing orders for administration of hepatitis B vaccination beginning at birth; 2) instituting delivery hospital policies and procedures and case management programs to improve identification of and administration of immunoprophylaxis to infants born to mothers who are hepatitis B surface antigen (HBsAg) positive and to mothers with unknown HBsAg status at the time of delivery; and 3) implementing vaccination record reviews for all children aged 11--12 years and children and adolescents aged <19 years who were born in countries with intermediate and high levels of HBV endemicity, adopting hepatitis B vaccine requirements for school entry, and integrating hepatitis B vaccination services into settings that serve adolescents. The second part of the ACIP statement, which will include updated recommendations and strategies to increase hepatitis B vaccination of adults, will be published separately.prepared by Eric E. Mast, Harold S. Margolis, Anthony E. Fiore, Edward W. Brink, Susan T. Goldstein, Susan A. Wang, Linda A. Moyer,, Beth P. Bell, Miriam J. Alter.The material in this report originated in the National Center for Infectious Diseases, Rima F. Khabbaz, MD, Director, Division of Viral Hepatitis, John W. Ward, MD, Director; and the National Immunization Program, Anne Schuchat, MD, Director, Immunization Services Division, Lance E. Rodewald, MD, Director.Includes bibliographical references (p. 18-23).16371945Infectious DiseasePrevention and ControlCurrentACI

Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP)

prepared by Carolyn B. Bridges, Keiji Fukuda, Timothy M. Uyeki, Nancy J. Cox, James A. Singleton.Includes bibliographical references (p. 24-31).Infectious DiseasePrevention and ControlSupersededACIP1/13/2014JCSmit